Literature DB >> 29269663

Vascular Lake Phenomenon.

Akira Kuriyama1, Etsuro Sakata2, Tomohiko Sunami3.   

Abstract

Entities:  

Keywords:  DEB-TACE; chemoembolization; doxorubicin; drug-eluting beads; hepatocellular carcinoma; vascular lake

Year:  2017        PMID: 29269663      PMCID: PMC5919876          DOI: 10.2169/internalmedicine.9592-17

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


× No keyword cloud information.
A 76-year-old man with hepatitis B-associated hepatocellular carcinoma (HCC) had multiple episodes of HCC recurrence despite repeated transcatheter arterial chemoembolization (TACE). Thus, drug-eluting bead TACE (DEB-TACE) was performed for a tumor measuring 4 cm in diameter (Picture). Digital-subtraction angiography after the procedure showed stasis in the feeding artery and localized pooling of the contrast medium within the tumor, namely, the “vascular lake phenomenon (VLP)” (arrowheads, Picture). This vascular lake disappeared after embolization.
Picture.
DEB-TACE is a chemoembolization technique using drug-eluting beads, which ensure prolonged and sustained intratumoral drug release. The technique is associated with a higher response rate and overall survival in comparison with conventional TACE (1). Although its cause remains unclear, the VLP occurs during DEB-TACE in large encapsulated tumors; the incidence in treated nodules is 12-26% (2, 3). The VLP is reported to be associated with a good local and overall response to chemoembolization (2, 3). Given the recent introduction and growing use of DEB-TACE in Japan, physicians need to be aware of the VLP.

The authors state that they have no Conflict of Interest (COI).
  3 in total

1.  Management of vascular lake phenomenon on angiography during chemoembolization with superabsorbent polymer microspheres.

Authors:  Akihiko Seki; Shinichi Hori; Chigusa Shimono
Journal:  Jpn J Radiol       Date:  2015-10-22       Impact factor: 2.374

2.  Occurrence of Vascular Lake Phenomenon as a Predictor of Improved Tumor Response in HCC Patients That Underwent DEB-TACE.

Authors:  Rafael Noronha Cavalcante; Felipe Nasser; Joaquim M Motta-Leal-Filho; Breno B Affonso; Francisco L Galastri; Bruna De Fina; Rodrigo G Garcia; Nelson Wolosker
Journal:  Cardiovasc Intervent Radiol       Date:  2017-05-12       Impact factor: 2.740

3.  Efficacy and safety of cTACE versus DEB-TACE in patients with hepatocellular carcinoma: a meta-analysis.

Authors:  Jing Huai Zou; Lan Zhang; Zheng Gang Ren; Sheng Long Ye
Journal:  J Dig Dis       Date:  2016-08       Impact factor: 2.325

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.